Publications by authors named "Donald Milligan"

Claim this Profile
E
Eradication of minimal residual disease improves overall and progression-free survival in patients with chronic lymphocytic leukaemia, evidence from NCRN CLL207: a phase II trial assessing alemtuzumab consolidation.
Abraham M Varghese, Dena R Howard, Christopher Pocock, Andy C Rawstron, George Follows, Donald Milligan

Br J Haematol· February 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An operational definition of primary refractory acute myeloid leukemia allowing early identification of patients who may benefit from allogeneic stem cell transplantation.
Paul Ferguson, Robert K Hills, Angela Grech, Sophie Betteridge, Lars Kjeldsen, Donald Milligan

Haematologica· November 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and Efficacy of Fedratinib in Patients With Primary or Secondary Myelofibrosis: A Randomized Clinical Trial.
Animesh Pardanani, Claire Harrison, Jorge E Cortes, Francisco Cervantes, Ruben A Mesa, Donald Milligan

JAMA Oncol· August 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Final results of EFC6663: a multicenter, international, phase 2 study of alvocidib for patients with fludarabine-refractory chronic lymphocytic leukemia.
Mark C Lanasa, Leslie Andritsos, Jennifer R Brown, Janice Gabrilove, Federico Caligaris-Cappio, Donald W Milligan

Leuk Res· May 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rituximab plus chlorambucil as first-line treatment for chronic lymphocytic leukemia: Final analysis of an open-label phase II study.
Peter Hillmen, John G Gribben, George A Follows, Donald Milligan, Hazem A Sayala

J Clin Oncol· April 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Improved relapse-free survival after autologous stem cell transplantation does not translate into better quality of life in chronic lymphocytic leukemia: lessons from the randomized European Society for Blood and Marrow Transplantation-Intergroup study.
Liesbeth C de Wreede, Maggie Watson, Marleen van Os, Donald Milligan, Michel van Gelder

Am J Hematol· February 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Optimization of chemotherapy for younger patients with acute myeloid leukemia: results of the medical research council AML15 trial.
Alan K Burnett, Nigel H Russell, Robert K Hills, Ann E Hunter, Lars Kjeldsen, Donald Milligan

J Clin Oncol· September 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clofarabine doubles the response rate in older patients with acute myeloid leukemia but does not improve survival.
Alan K Burnett, Nigel H Russell, Ann E Hunter, Donald Milligan, Steven Knapper

Blood· August 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Curability of patients with acute myeloid leukemia who did not undergo transplantation in first remission.
Alan K Burnett, Anthony Goldstone, Robert K Hills, Donald Milligan, Archie Prentice

J Clin Oncol· April 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Addition of gemtuzumab ozogamicin to induction chemotherapy improves survival in older patients with acute myeloid leukemia.
Alan K Burnett, Nigel H Russell, Robert K Hills, Jonathan Kell, Sylvie Freeman, Donald Milligan

J Clin Oncol· November 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The addition of the farnesyl transferase inhibitor, tipifarnib, to low dose cytarabine does not improve outcome for older patients with AML.
Alan K Burnett, Nigel H Russell, Dominic Culligan, Jamie Cavanagh, Jonathan Kell, Donald Milligan

Br J Haematol· August 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Autologous hematopoietic stem cell transplantation in chronic lymphocytic leukemia: results of European intergroup randomized trial comparing autografting versus observation.
Mauricette Michallet, Peter Dreger, Laurent Sutton, Ronald Brand, Sue Richards, Donald Milligan

Blood· February 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial.
Alan K Burnett, Robert K Hills, Donald Milligan, Lars Kjeldsen, Jonathan Kell

J Clin Oncol· February 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Allogeneic transplant outcomes are not affected by body mass index (BMI) in patients with haematological malignancies.
Emmanouil Nikolousis, Sandeep Nagra, Shankara Paneesha, Julio Delgado, Kathy Holder, Donald Milligan

Ann Hematol· November 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of in vivo alemtuzumab dose before reduced intensity conditioning and HLA-identical sibling stem cell transplantation: pharmacokinetics, GVHD, and immune reconstitution.
Ronjon Chakraverty, Guillermo Orti, Michael Roughton, Jun Shen, Adele Fielding, Donald Milligan

Blood· October 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Factors predicting long-term survival after T-cell depleted reduced intensity allogeneic stem cell transplantation for acute myeloid leukemia.
Charles Craddock, Sandeep Nagra, Andrew Peniket, Cassandra Brookes, Laura Buckley, Donald Milligan

Haematologica· June 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
European development of clofarabine as treatment for older patients with acute myeloid leukemia considered unsuitable for intensive chemotherapy.
Alan K Burnett, Nigel H Russell, Jonathan Kell, Michael Dennis, Donald Milligan

J Clin Oncol· May 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The impact on outcome of the addition of all-trans retinoic acid to intensive chemotherapy in younger patients with nonacute promyelocytic acute myeloid leukemia: overall results and results in genotypic subgroups defined by mutations in NPM1, FLT3, and CEBPA.
Alan K Burnett, Robert K Hills, Claire Green, Sarah Jenkinson, Kenneth Koo, Donald W Milligan

Blood· February 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Attempts to optimize induction and consolidation treatment in acute myeloid leukemia: results of the MRC AML12 trial.
Alan K Burnett, Robert K Hills, Donald W Milligan, Anthony H Goldstone, Archibald G Prentice

J Clin Oncol· February 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Allogeneic hematopoietic cell transplantation for chronic lymphocytic leukemia: ready for prime time?
Julio Delgado, Donald W Milligan, Peter Dreger

Blood· September 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
"
"Viral" myocarditis in a patient following allogenic stem cell transplant: diagnostic dilemma and management considerations.
Sanjay Bhattacharya, Shankara Paneesha, Sridhar Chaganti, Richard Lovell, Gareth Slocombe, Donald Milligan

J Clin Virol· July 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic factor analysis of the survival of elderly patients with AML in the MRC AML11 and LRF AML14 trials.
Keith Wheatley, Cassandra L Brookes, Andrew J Howman, Anthony H Goldstone, Donald W Milligan

Br J Haematol· June 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Beta2-microglobulin is a better predictor of treatment-free survival in patients with chronic lymphocytic leukaemia if adjusted according to glomerular filtration rate.
Julio Delgado, Guy Pratt, Neil Phillips, Javier Briones, Chris Fegan, Donald Milligan

Br J Haematol· June 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The impact of dose escalation and resistance modulation in older patients with acute myeloid leukaemia and high risk myelodysplastic syndrome: the results of the LRF AML14 trial.
Alan K Burnett, Donald Milligan, Anthony Goldstone, Archibald Prentice, Mary-Frances McMullin

Br J Haematol· May 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The effect of in vivo T cell depletion with alemtuzumab on reduced-intensity allogeneic hematopoietic cell transplantation for chronic lymphocytic leukemia.
Julio Delgado, Srinivas Pillai, Reuben Benjamin, Dolores Caballero, Rodrigo Martino, Donald Milligan

Biol Blood Marrow Transplant· November 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis